116 related articles for article (PubMed ID: 36077756)
1. Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
Russell S; Lim F; Peters PN; Wardell SE; Whitaker R; Chang CY; Previs RA; McDonnell DP
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077756
[TBL] [Abstract][Full Text] [Related]
2. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.
McCloskey CW; Goldberg RL; Carter LE; Gamwell LF; Al-Hujaily EM; Collins O; Macdonald EA; Garson K; Daneshmand M; Carmona E; Vanderhyden BC
Front Oncol; 2014; 4():53. PubMed ID: 24672774
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer.
Cook DP; Galpin KJC; Rodriguez GM; Shakfa N; Wilson-Sanchez J; Echaibi M; Pereira M; Matuszewska K; Haagsma J; Murshed H; Cudmore AO; MacDonald E; Tone A; Shepherd TG; Petrik JJ; Koti M; Vanderhyden BC
Commun Biol; 2023 Nov; 6(1):1152. PubMed ID: 37957414
[TBL] [Abstract][Full Text] [Related]
4. Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma.
Liu P; Chen R; Zhang X; Fu R; Tao L; Jia W
BMC Genomics; 2022 Jan; 23(1):51. PubMed ID: 35026984
[TBL] [Abstract][Full Text] [Related]
5. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
7. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
8. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract][Full Text] [Related]
9. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.
Iyer S; Zhang S; Yucel S; Horn H; Smith SG; Reinhardt F; Hoefsmit E; Assatova B; Casado J; Meinsohn MC; Barrasa MI; Bell GW; Pérez-Villatoro F; Huhtinen K; Hynninen J; Oikkonen J; Galhenage PM; Pathania S; Hammond PT; Neel BG; Farkkila A; Pépin D; Weinberg RA
Cancer Discov; 2021 Feb; 11(2):384-407. PubMed ID: 33158843
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
12. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
13. Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
Whitehair R; Peres LC; Mills AM
Int J Gynecol Pathol; 2020 Nov; 39(6):558-566. PubMed ID: 31851060
[TBL] [Abstract][Full Text] [Related]
14. Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy.
Gautam A; Beiss V; Wang C; Wang L; Steinmetz NF
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575893
[TBL] [Abstract][Full Text] [Related]
15. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
18. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract][Full Text] [Related]
19. An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.
Nunez-Cruz S; Connolly DC; Scholler N
J Vis Exp; 2010 Nov; (45):. PubMed ID: 21178956
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Hayakawa T; Yaguchi T; Kawakami Y
Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
